ATE140968T1 - Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert - Google Patents

Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert

Info

Publication number
ATE140968T1
ATE140968T1 AT90907682T AT90907682T ATE140968T1 AT E140968 T1 ATE140968 T1 AT E140968T1 AT 90907682 T AT90907682 T AT 90907682T AT 90907682 T AT90907682 T AT 90907682T AT E140968 T1 ATE140968 T1 AT E140968T1
Authority
AT
Austria
Prior art keywords
vascular endothelial
growth factor
cell growth
endothelial cell
culture
Prior art date
Application number
AT90907682T
Other languages
English (en)
Inventor
Napoleone Ferrara
David Wai-Hung Leung
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE140968T1 publication Critical patent/ATE140968T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT90907682T 1989-05-12 1990-05-09 Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert ATE140968T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35111789A 1989-05-12 1989-05-12
US36942489A 1989-06-21 1989-06-21
US07/389,722 US5332671A (en) 1989-05-12 1989-08-04 Production of vascular endothelial cell growth factor and DNA encoding same

Publications (1)

Publication Number Publication Date
ATE140968T1 true ATE140968T1 (de) 1996-08-15

Family

ID=27407983

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90907682T ATE140968T1 (de) 1989-05-12 1990-05-09 Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert

Country Status (14)

Country Link
US (2) US5332671A (de)
EP (1) EP0471754B1 (de)
JP (1) JP3117992B2 (de)
AT (1) ATE140968T1 (de)
AU (1) AU635935B2 (de)
CA (1) CA2054699C (de)
DE (1) DE69027990T2 (de)
DK (1) DK0471754T3 (de)
ES (1) ES2093025T3 (de)
IE (1) IE74169B1 (de)
IL (2) IL94128A (de)
NZ (1) NZ233451A (de)
PT (1) PT93996B (de)
WO (1) WO1990013649A1 (de)

Families Citing this family (168)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
IL93846A0 (en) * 1989-03-24 1990-12-23 Univ California Endothelial cell growth factor,methods of isolation and expression
ZA903485B (en) * 1989-05-12 1992-01-29 Genentech Inc Production of vascular endothelial cell growth factor and dna encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US7300791B2 (en) * 1989-05-12 2007-11-27 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
EP0399816B1 (de) * 1989-05-24 1995-12-20 Merck & Co. Inc. Reinigung und Charakterisierung eines von einem Glioma abstammenden Wachstumsfaktors
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6083220A (en) 1990-03-13 2000-07-04 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42756E1 (en) 1990-03-13 2011-09-27 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
USRE42625E1 (en) 1990-03-13 2011-08-16 The Regents Of The University Of California Endovascular electrolytically detachable wire and tip for the formation of thrombus in arteries, veins, aneurysms, vascular malformations and arteriovenous fistulas
DE69229454T2 (de) * 1991-03-28 2000-01-05 Merck & Co., Inc. Untereinheit-C des vaskulären endothelialen Zellwachstumsfaktors
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
EP0550296A3 (en) * 1991-11-28 1993-12-29 Terumo Corp Vascular endothelial cells growth factor
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP0666868B2 (de) * 1992-10-28 2006-06-14 Genentech, Inc. Verwendung von anti-VEGF Antikörpern zur Behandlung von Krebs
US5731294A (en) * 1993-07-27 1998-03-24 Hybridon, Inc. Inhibition of neovasularization using VEGF-specific oligonucleotides
US5464815A (en) * 1993-09-08 1995-11-07 Genentech, Inc. Inhibition of heparin-binding
GB9402857D0 (en) 1994-02-15 1994-04-06 Isis Innovation Targeting gene therapy
US6152141A (en) * 1994-07-28 2000-11-28 Heartport, Inc. Method for delivery of therapeutic agents to the heart
WO1996006641A1 (en) * 1994-08-29 1996-03-07 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6221839B1 (en) * 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US7160991B1 (en) 1995-03-02 2007-01-09 Ludwig Institute For Cancer Research Vascular endothelial growth factor polypeptides
HU223438B1 (hu) * 1995-03-02 2004-07-28 Amrad Operations Pty. Ltd. Új növekedési faktor és ezt kódoló génszekvencia
EP0821728B1 (de) 1995-04-06 2004-08-11 Regeneron Pharmaceuticals, Inc. Tie-2 liganden, herstellungsverfahren und verwendung
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
EP0873348A4 (de) * 1995-06-06 2000-11-08 Human Genome Sciences Inc Menschlicher vaskularer endothelialer wachtumsfaktor 3
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) * 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US6020473A (en) * 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
US7005505B1 (en) 1995-08-25 2006-02-28 Genentech, Inc. Variants of vascular endothelial cell growth factor
ATE242809T1 (de) 1995-09-08 2003-06-15 Genentech Inc Vegf-verwandtes protein
US5830879A (en) * 1995-10-02 1998-11-03 St. Elizabeth's Medical Center Of Boston, Inc. Treatment of vascular injury using vascular endothelial growth factor
EP0888086B1 (de) 1996-02-15 2005-07-27 Biosense Webster, Inc. Sonde zur exkavation
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
EP0935415B1 (de) * 1996-05-01 2006-11-22 Imarx Pharmaceutical Corp. In vitro verfahren zum einbringen von nukleinsäuren in eine zelle
US6846914B2 (en) * 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
AU724467B2 (en) * 1996-06-19 2000-09-21 Regeneron Pharmaceuticals, Inc. TIE-2 receptor ligand (TIE ligand-4) and its uses
US6443974B1 (en) 1996-07-28 2002-09-03 Biosense, Inc. Electromagnetic cardiac biostimulation
AU738806B2 (en) 1996-09-24 2001-09-27 Merck & Co., Inc. Gene therapy for inhibition of angiogenesis
HUP0001964A3 (en) 1997-01-29 2002-01-28 Cornell Res Foundation Inc Ith Multiple site delivery of adenoviral vector for the induction of angiogenesis
US7125714B2 (en) * 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6395707B1 (en) 1997-02-14 2002-05-28 Genentech, Inc. Methods of treatment utilizing variants of vascular endothelial cell growth factor
US6485942B1 (en) * 1997-02-14 2002-11-26 Genentech, Inc. Variants of vascular endothelial cell growth factor having altered pharmacological properties, and recombinant methods of production
US6613563B1 (en) 1997-03-14 2003-09-02 Selective Gentics, Inc. Viral vectors with modified tropism
CN101665536B (zh) 1997-04-07 2013-07-03 基因技术股份有限公司 抗-血管内皮生长因子的抗体
US6031155A (en) * 1997-06-05 2000-02-29 Cameron-Mills; Verena Arabinoxylan degradation
EP1009814B1 (de) 1997-06-18 2007-08-29 Merck & Co., Inc. (a New Jersey corp.) Kdr, ein menschlicher tyrosin kinase rezeptor
US6391311B1 (en) 1998-03-17 2002-05-21 Genentech, Inc. Polypeptides having homology to vascular endothelial cell growth factor and bone morphogenetic protein 1
US20030113303A1 (en) * 1998-02-05 2003-06-19 Yitzhack Schwartz Homing of embryonic stem cells to a target zone in tissue using active therapeutics or substances
EP1563866B1 (de) 1998-02-05 2007-10-03 Biosense Webster, Inc. Gerät zum Freisetzen eines Medikaments im Herzen
US20030129750A1 (en) * 1998-02-05 2003-07-10 Yitzhack Schwartz Homing of donor cells to a target zone in tissue using active therapeutics or substances
WO1999040197A2 (en) 1998-02-06 1999-08-12 Collateral Therapeutics, Inc. Variants of the angiogenic factor vascular endothelial cell growth factor: vegf
US6479729B1 (en) 1998-02-06 2002-11-12 The Johns Hopkins University Mouse model for ocular neovascularization
US6676937B1 (en) * 1998-03-09 2004-01-13 Caritas St. Elizabeth's Medical Center Of Boston Inc. Compositions and methods for modulating vascularization
US20040228834A1 (en) * 1998-03-09 2004-11-18 Jeffrey Isner Compositions and methods for modulating vascularization
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
PT2016951E (pt) 1998-03-17 2012-09-27 Genentech Inc Polipéptidos homólogos de vegf e de bmp1
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6677300B1 (en) * 1998-09-09 2004-01-13 Scios, Inc. Treatment of microvascular angiopathies
US7030083B2 (en) * 1998-09-09 2006-04-18 University Of Washington Treatment of eclampsia and preeclampsia
EP1417971A3 (de) * 1998-09-09 2004-06-30 Scios Inc. Verwendung eines angiogenen Faktors zur Behandlung von mikrovaskulären Angiopathien
IL141687A0 (en) * 1998-09-09 2002-03-10 Scios Inc Treatment of microvascular angiopathies
EP1447089A3 (de) * 1998-09-09 2004-12-15 Scios Inc. Methoden zur Behandlung von Hypertonie und Zusammensetzungen dafür
US6783953B1 (en) 1998-12-22 2004-08-31 Janssen Pharmaceutica N.V. Vascular endothelial growth factor-X
DK1140173T4 (da) 1998-12-22 2013-06-10 Genentech Inc Vaskulære endothelcellevækstfaktorantagonister og anvendelser deraf
WO2000047040A1 (en) * 1999-02-11 2000-08-17 The Schepens Eye Research Institute, Inc. Growth medium for human corneal endothelial cells
EP2357192A1 (de) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Menschliches alpha-Endokin und Verfahren zu seiner Verwendung
US7090834B1 (en) 1999-04-16 2006-08-15 Genentech, Inc. Vascular endothelial cell growth factor variants and uses thereof
ES2223705T3 (es) 1999-04-28 2005-03-01 Board Of Regents, The University Of Texas System Composiciones y metodos para el tratamiento de cancer mediante inhibi cion selectiva del vegf.
US6475796B1 (en) 1999-05-20 2002-11-05 Scios, Inc. Vascular endothelial growth factor variants
WO2000071716A2 (en) * 1999-05-20 2000-11-30 Scios Inc. Vascular endothelial growth factor dimers
AU5624400A (en) * 1999-06-18 2001-01-09 Collaborative Group, Ltd., The Hyaluronic acid film and matrix for sustained gene transfer
US7101706B1 (en) * 1999-06-25 2006-09-05 Insight Biopharmaceuticals Ltd. Polynucleotides and polypeptides encoded thereby distantly homologous to heparanase
DE19940012A1 (de) * 1999-08-24 2001-03-08 Karin Faerber Neues Mittel aus mindestens zwei Komponenten, das zum einen Gefäßneubildung (Neoangiogense) induziert des weiteren jedoch auch Gefäßverschlüsse (Restenosen) verhindert, das Verfahren seiner Herstellung und seine Verwendung
US7078382B1 (en) 1999-11-02 2006-07-18 Genentech, Inc. Modulation of eNOS activity and therapeutic uses thereof
CA2654413C (en) * 2000-04-12 2016-10-18 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of vegf and homologues to treat neuron disorders
JP2003530838A (ja) 2000-04-12 2003-10-21 ヒューマン ゲノム サイエンシズ インコーポレイテッド アルブミン融合タンパク質
CA2648051A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
DK2042597T3 (da) 2000-06-23 2014-08-11 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af sygdomme, der involverer angiogenese
KR100419972B1 (ko) * 2000-09-09 2004-03-03 굿젠 주식회사 링커 염기서열로 연결된 인간 ｖｅｇｆ의 돌연변이형동형이합체 유전자, 이를 포함하는 발현벡터, 이의형질전환체 및 단백질
US6506365B1 (en) 2000-09-25 2003-01-14 Baxter Aktiengesellschaft Fibrin/fibrinogen binding conjugate
EP1341914A2 (de) * 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation der angiogenese durch zinkfinger-proteine
US7067317B2 (en) * 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
NZ530582A (en) 2001-07-17 2008-06-30 Res Dev Foundation Therapeutic agents comprising pro-apoptotic proteins, including granzyme, bax and TNF
KR100942880B1 (ko) 2001-08-29 2010-02-17 제넨테크, 인크. 유사분열촉진 활성을 가진 Ｂｖ８ 핵산 및 폴리펩티드
AU2002328200B2 (en) * 2001-09-27 2008-01-03 Bionomics Limited DNA sequences for human angiogenesis genes
NZ543295A (en) * 2001-09-27 2008-04-30 Bionomics Ltd DNA sequences for human angiogenesis genes
US6953241B2 (en) 2001-11-30 2005-10-11 Brother Kogyo Kabushiki Kaisha Ink-jet head having passage unit and actuator units attached to the passage unit, and ink-jet printer having the ink-jet head
US7795213B2 (en) * 2001-12-13 2010-09-14 Posco Methods of contacting β amyloid protein with VEGF
US20030171556A1 (en) * 2001-12-13 2003-09-11 Chi-Bom Chae Beta-amyloid binding factors and inhibitors thereof
ES2425738T3 (es) 2001-12-21 2013-10-17 Human Genome Sciences, Inc. Proteínas de fusión de la albúmina
US7081443B2 (en) * 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US7435419B2 (en) 2002-07-19 2008-10-14 Beth Israel Deaconess Medical Center Methods of diagnosing and treating pre-eclampsia or eclampsia
DK2308507T3 (da) 2002-07-19 2015-04-20 Beth Israel Hospital Fremgangsmåder til behandling af præeklampsi
US7335362B2 (en) * 2002-07-19 2008-02-26 Beth Israel Deaconess Medical Center Methods of treating pre-eclampsia or eclampsia
CA2512624A1 (en) * 2003-01-29 2004-08-19 Merck & Co., Inc. Rat receptor tyrosine kinase, kdr
MXPA05009743A (es) * 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
US7259140B2 (en) 2003-03-28 2007-08-21 Thomas Jefferson University Heparin-binding peptides and uses thereof
US7601341B2 (en) 2003-06-05 2009-10-13 Research Development Foundation Vascular endothelial growth factor fusion constructs used to inhibit osteoclastogenesis
US8273383B2 (en) * 2004-05-04 2012-09-25 Children's Medical Center Corporation Methods and compositions for treatment of preeclampsia
RS51481B (sr) 2004-05-27 2011-04-30 Vib, Vzw Lečenje amiotrofične lateralne skleroze
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1789074A4 (de) * 2004-08-09 2009-08-12 Alios Biopharma Inc Synthetische hyperglycosylierte, protease-resistente polypeptid-varianten, orale formulierungen und anwendungsverfahren dafür
AR050608A1 (es) * 2004-08-19 2006-11-08 Alza Corp Aparato y metodo para administracion transdermica de factores de crecimiento endotelial vascular
DK1804836T3 (da) 2004-09-24 2011-01-24 Beth Israel Hospital Fremgangsmåder til diagnosticering og behandling af graviditetskomplikationer
US7740849B2 (en) * 2004-09-24 2010-06-22 Beth Israel Deaconess Medical Center Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US7691365B2 (en) 2004-09-28 2010-04-06 Aprogen, Inc. Methods of using chimeric coiled coil molecule to treat ischemic disease
JP2008523816A (ja) * 2004-12-15 2008-07-10 ベス イスラエル ディーコネス メディカル センター 妊娠合併症の診断および処置に有用な核酸およびポリペプチド
US7358085B2 (en) 2005-02-28 2008-04-15 Sangamo Biosciences, Inc. Anti-angiogenic methods and compositions
US7893244B2 (en) * 2005-04-12 2011-02-22 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
AU2006235489A1 (en) * 2005-04-12 2006-10-19 Intradigm Corporation Composition and methods of RNAi therapeutics for treatment of cancer and other neovascularization diseases
KR20080017362A (ko) * 2005-06-17 2008-02-26 제넨테크, 인크. 창상 치유를 위한 ｖｅｇｆ의 용도
DE602006020881D1 (de) 2005-08-15 2011-05-05 Vegenics Pty Ltd Enen eigenschaften
US8329175B2 (en) * 2005-08-26 2012-12-11 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the treatment and diagnosis of endothelial cell disorders and angiogenic disorders
NZ568809A (en) * 2005-12-22 2011-08-26 Genentech Inc Recovering and purification of VEGF proteins from prokaryotic cells using polyanionic agents
US20090286271A1 (en) * 2006-05-31 2009-11-19 Karumanchi Ananth S Methods of Diagnosing and Treating Complications of Pregnancy
AU2007272412B2 (en) 2006-07-14 2013-11-07 Genentech, Inc. Refolding of recombinant proteins
US8110720B2 (en) * 2006-12-22 2012-02-07 Genentech, Inc Transgenic mice expressing humanized VEGF
EP2139447A2 (de) 2007-03-20 2010-01-06 Harold Brem Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
WO2008116111A2 (en) * 2007-03-20 2008-09-25 Harold Brem Growth factor mediated cosmeceuticals and use thereof to enhance skin quality
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
KR101642846B1 (ko) 2007-12-26 2016-07-26 백시넥스 인코포레이티드 항-ｃ35 항체 병용 치료 및 방법
KR101762306B1 (ko) 2008-01-18 2017-07-27 낫코 파마 리미티드 암과 관련된 질환의 치료에 유용한 6,7-디알콕시 퀴나졸린 유도체
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
US9050341B2 (en) 2009-07-14 2015-06-09 Natco Pharma Limited Methods of treating drug resistant and other tumors by administering 6,7-dialkoxy quinazoline derivatives
US8969322B2 (en) 2010-05-14 2015-03-03 Beth Israel Deconess Medical Center, Inc. Extracorporeal devices and methods of treating complications of pregnancy
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
DK4108671T3 (da) 2010-10-01 2025-01-06 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer samt anvendelser deraf
JP2014511687A (ja) 2011-03-31 2014-05-19 モデルナ セラピューティクス インコーポレイテッド 工学操作された核酸の送達および製剤
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
JP6113737B2 (ja) 2011-10-03 2017-04-12 モデルナティエックス インコーポレイテッドＭｏｄｅｒｎａＴＸ，Ｉｎｃ． 修飾型のヌクレオシド、ヌクレオチドおよび核酸、ならびにそれらの使用方法
KR20140102759A (ko) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물
CA2859691A1 (en) * 2011-12-21 2013-06-27 Moderna Therapeutics, Inc. Methods of increasing the viability or longevity of an organ or organ explant
EP2834259A4 (de) 2012-04-02 2016-08-24 Moderna Therapeutics Inc Modifizierte polynukleotide
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
EP3613847A1 (de) 2013-03-13 2020-02-26 The University of Queensland Verfahren zur isolierung von zellen zur therapie und prophylaxe
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP3052521A1 (de) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
DK3277815T3 (da) 2015-04-03 2021-12-13 Univ Massachusetts Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
WO2016161388A1 (en) 2015-04-03 2016-10-06 University Of Massachusetts Fully stabilized asymmetric sirna
EP3334499A4 (de) 2015-08-14 2019-04-17 University of Massachusetts Bioaktive konjugaten zur freisetzung von oligonukleotiden
MX394263B (es) 2015-08-17 2025-03-24 Lupin Ltd Proceso de replegamiento mejorado para los fragmentos de anticuerpo
US10478503B2 (en) 2016-01-31 2019-11-19 University Of Massachusetts Branched oligonucleotides
WO2018031933A2 (en) 2016-08-12 2018-02-15 University Of Massachusetts Conjugated oligonucleotides
CN110799647A (zh) 2017-06-23 2020-02-14 马萨诸塞大学 双尾自递送sirna及相关的方法
AU2019316640B2 (en) 2018-08-10 2026-03-12 University Of Massachusetts Modified oligonucleotides targeting SNPs
EP3840759A4 (de) 2018-08-23 2022-06-01 University Of Massachusetts O-methyl-reiche vollstabilisierte oligonukleotide
AU2020207935A1 (en) 2019-01-18 2021-08-26 University Of Massachusetts Dynamic pharmacokinetic-modifying anchors
KR20220047989A (ko) 2019-08-09 2022-04-19 유니버시티 오브 매사추세츠 Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
EP3882264A1 (de) * 2020-03-20 2021-09-22 Universität zu Köln Vegf-dimer-moleküle und säulen mit einem vegf-dimer-molekül sowie verwendungen, herstellungsverfahren und verfahren unter verwendung davon
US12534724B2 (en) 2020-05-26 2026-01-27 University Of Massachusetts Synthetic oligonucleotides having regions of block and cluster modifications
IL309334A (en) 2021-06-23 2024-02-01 Univ Massachusetts Anti-FLT1 optimized oligonucleotide compounds for the treatment of preeclampsia and other angiogenic disorders
KR20240170849A (ko) * 2022-03-08 2024-12-04 예일 유니버시티 선택적 림프 자극을 위한 vegf-c 뮤테인

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US456550A (en) * 1891-07-28 Shuttle-box-operating mechanism for looms
US4456550A (en) * 1982-11-22 1984-06-26 President And Fellows Of Harvard College Vascular permeability factor
US4863899A (en) * 1983-05-09 1989-09-05 Todaro George J Biologically active polypeptides
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
US4721672A (en) * 1985-08-28 1988-01-26 President And Fellows Of Harvard College CDNA and gene for human angiogenin (angiogenesis factor) and methods of expression
US5073492A (en) * 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
US5008196A (en) * 1987-08-21 1991-04-16 Monsanto Company Stimulation of endothelial cell growth
US5240848A (en) * 1988-11-21 1993-08-31 Monsanto Company Dna sequences encoding human vascular permeability factor having 189 amino acids
US5227302A (en) * 1988-12-20 1993-07-13 Ludwig Institute For Cancer Research DNA encoding platelet derived endothelial cell growth factor (PD-ECGF)
IL93846A0 (en) * 1989-03-24 1990-12-23 Univ California Endothelial cell growth factor,methods of isolation and expression
US6899882B1 (en) * 1989-03-24 2005-05-31 The Regents Of The University Of California Endothelial cell growth factor methods of isolation and expression
ZA903485B (en) * 1989-05-12 1992-01-29 Genentech Inc Production of vascular endothelial cell growth factor and dna encoding same
US5332671A (en) * 1989-05-12 1994-07-26 Genetech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US20030114374A1 (en) * 1989-05-12 2003-06-19 Genentech, Inc. Production of vascular endothelial cell growth factor and DNA encoding same
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5219739A (en) * 1989-07-27 1993-06-15 Scios Nova Inc. DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121

Also Published As

Publication number Publication date
ES2093025T3 (es) 1996-12-16
IL154797A0 (en) 2003-10-31
PT93996B (pt) 1997-09-30
DE69027990T2 (de) 1997-01-30
US20070161558A1 (en) 2007-07-12
CA2054699C (en) 2002-07-02
IL94128A0 (en) 1991-01-31
JP3117992B2 (ja) 2000-12-18
IE901494L (en) 1990-11-12
AU5657490A (en) 1990-11-29
EP0471754A1 (de) 1992-02-26
AU635935B2 (en) 1993-04-08
DK0471754T3 (da) 1996-11-04
IE74169B1 (en) 1997-07-02
NZ233451A (en) 1992-10-28
JPH04505705A (ja) 1992-10-08
PT93996A (pt) 1991-01-08
US5332671A (en) 1994-07-26
EP0471754B1 (de) 1996-07-31
WO1990013649A1 (en) 1990-11-15
DE69027990D1 (de) 1996-09-05
IL94128A (en) 2005-11-20
CA2054699A1 (en) 1990-11-13

Similar Documents

Publication Publication Date Title
ATE140968T1 (de) Kultur des wachstumsfaktors der vaskularen endothelialzellen und dns, die dafür kodiert
ES2094159T3 (es) Produccion de factor de crecimiento de celulas endoteliales vasculares.
ATE274577T1 (de) Stammzellen-proliferations-faktor
ATE110108T1 (de) Genetische modifizierung von endothelialen zellen.
ES8600613A1 (es) Procedimiento para el tratamiento de tejidos corporales
DE3684078D1 (de) Reinigung und aktivierung von proteinen aus unloeslichen einschlusskoerpern.
ES2109924T3 (es) Metodo rapido, versatil y simple de expresion de genes en celulas eucarioticas.
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
LU90855I2 (en) Proteine 1 osteogenique recombinante humaine: bmp-7 et ses d-riv-s pharmaceutiquement acceptables
DE69736391D1 (de) Verfahren zur herstellung eines rekombinanten polypeptids unter hinzufügung eines hemmstoffes einer metallabhängigen protease oder chymotrypsins zum zellkulturmedium
EP0216742A3 (de) Wachstumsfaktoren
EP0230945A3 (en) Thrombin-binding substance and process for preparing thethrombin-binding substance and process for preparing the same same
EP0869970A4 (de) Vermehrungsinhibitoren von endothellzellen und verfahren zur anwendung
HU895788D0 (en) Process for producing peptides and medical products containing them
DE59410132D1 (de) Humanes zirkulierendes cytokin cc-1
ES2058343T3 (es) Piridinas disubstituidas.
DE69624918D1 (de) Verwendung von pseudopterosin zur förderung der wundheilung
GR852771B (de)
ES2039578T3 (es) Procedimiento para producir mercapto-acilaminoacidos antihipertensivos.
ES2126575T3 (es) Sacarosa-fosfato-sintasa (sps), su procedimiento de preparacion, su adnc, y utilizacion de adnc para modificar la expresion de sps en celulas vegetales.
ES8702463A1 (es) Un procedimiento para preparar un material polimero hidrofilo basado en polisacaridos polipeptidos y -o proteinas y derivados acrilicos hidrofilos.
NO960710D0 (no) Nye tripeptider nyttige i immun- og CNS-terapi
DE69825307D1 (de) Verwendung von protein h als zytostattischer wirkstoff
DE59404726D1 (de) Angiogenin und/oder alpha1-microglobulin und/oder komplementfaktor d zur begrenzung der sekretion von proteinen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time